Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06273774 · ClinicalTrials.gov registry record · Phase 1
A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT06273774 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 34 participants.
The verdict
NCT06273774, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the safety and tolerability of elpipodect in participants with stable bipolar I disorder. There was no hypothesis testing in this study.
Interventions
- DRUG Placebo
- DRUG Elpipodect
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2024-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06273774
The ClinicalTrials.gov registry entry for NCT06273774 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06273774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06273774 about?
NCT06273774 is a clinical study titled "A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)". The goal of this study is to evaluate the safety and tolerability of elpipodect in participants with stable bipolar I disorder. There was no hypothesis testing in this study.
What is the current status of trial NCT06273774?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2024-04-08. Estimated completion is 2024-08-21.
What interventions are being tested in trial NCT06273774?
The interventions under investigation include: Placebo (DRUG), Elpipodect (DRUG).
Who is sponsoring clinical trial NCT06273774?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.